The Mega-Appeal of Nanomedicine
The European Union is banking on big returns from nanotechnology in the fight against AD. European Union Throws Megabucks at Nanomedicine EU Consortium Applies Nanotechnology to Study AD
6397 RESULTS
Sort By:
The European Union is banking on big returns from nanotechnology in the fight against AD. European Union Throws Megabucks at Nanomedicine EU Consortium Applies Nanotechnology to Study AD
Cerebrospinal Fluid Tau Climbs in Aβ Mouse Models Coverage Denial For Amyloid Scans Riles Alzheimer’s Community Pooled GWAS Reveals New Alzheimer’s Genes and Pathways Are Subtle Memory Concerns a Sign of Future Dementia? Clinical Trials Roundup: Four Hits
Experimental α7 Agonist Meets Cognitive and Clinical Endpoints New Assays for Aβ Oligomers in CSF Claim Femtogram Sensitivity Q&A With Roche’s CNS Leader Luca Santarelli When Is a C9ORF72 Repeat Expansion Not a C9ORF72 Repeat Expansion? Wave of Ne
Madrid: ICAD Conference Draws to a Close Madrid: BACE Found to Have Big Job in Wrapping Motoneurons Madrid: Why Do People Drop Out of Trials? Madrid: Stressed Brain—SNP Carriers Can Have Cake and Eat It Madrid: BACE News Roundup, Part 1 Madrid: BACE News
Philadelphia: All Eyes on PIB Imaging—Is It Coming Along? Philadelphia: All Is Not Well with the Statin Story Philadelphia: Can a Shrinking Brain Be Good for You? Philadelphia: Dementia Types Just Won’t Fit into Little Boxes Philadelphia: Diagnosis Light—
Stockholm: Visualizing Amyloid Biggest Draw at Imaging Symposium, Consensus Sought on Validation Stockholm: Chlamydia Triggers Amyloid Plaques in Mice Stockholm: Aph-1 and Pen-2: New Names in the Presenilin Debate Complete the Complex? Stockholm: Clusteri
Washington: Alzhemed Non-story Yields Spotlight to Phase 2 Treatments Washington: Shaking Up AD Treatment with Ketone Bodies Washington: Site-to-Site Differences Delay Result of Alzhemed Trial Washington: γ-secretase Inhibitor Survived Phase 2, Moving to
Chicago: Studies Probe Diminishing Placebo Decline, Part 1 Chicago: Studies Probe Diminishing Placebo Decline, Part 2 Chicago: ICAD Offered Mix Bag of Setbacks and Hopeful News Chicago: Trial Design Bedevils Search for New AD Drugs, Part 1 Chicago: The Ph
Vienna: New Genes, Anyone? ICAD Saves Best for Last Vienna: In Genetics, Bigger Is Better—Data Sharing Nets Three New Hits Vienna: Can a D-Peptide Turn Tiger Into Pussycat? Vienna: New Shoot Among Ashes of Drug Trials Vienna: New Tack to See Amyloid Oligo
Honolulu: FDA Approval in Sight for 18F Amyloid Tracer Florbetapir? Honolulu: Tomm40 Reported to Track With Brain Atrophy, Cognition Honolulu: TrialMatch Launched as AD Is Becoming “Desktop” Disease Honolulu: The Missing Link? Tau Mediates Aβ Toxicity at
Paris: Renamed ARIA, Vasogenic Edema Common to Anti-Amyloid Therapy Paris: Semagacestat Autopsy and Other News of Trial Tribulations Paris: More Trial News, Mixed at Best Paris: President and All, French Science Takes the Stage Paris: Beyond Genomics, Fre
Sixth Int. Conference on AD: Mechanisms of Neurodegenerative Conditions I Sixth Int. Conference on AD: Genetics I Sixth Int. Conference on AD: Monkey Brain Injections Sixth Int. Conference on AD: Cellular/Animal Models I Sixth Int. Conference on AD: Mecha
1998 Society for Neuroscience Meeting: α2-Macroglobulin 1998 Society of Neuroscience Meeting: AD Plaques Associated with Curvier Dendrites 1998 Society for Neuroscience Meeting: Aβ vs. APP Effects in Transgenics 1998 Society for Neuroscience Meeting: Fram
Society for Neuroscience Annual Meeting: β-Secretase Further Confirmed Society for Neuroscience Annual Meeting: Another APP Secretase? Society for Neuroscience Annual Meeting: Imaging Amyloid Plaques in the Living Mouse Soc for Neuroscience Ann Mtg: One γ
Society for Neuroscience Annual Meeting: Stem Cells Drawn to Aβ Society for Neuroscience Annual Meeting: Stem Cells Promising for Motor Neuron Disorders Society for Neuroscience Annual Meeting: Does ApoE Contribute to Tangle Formation? Society for Neurosc
No filters selected